ArticleInternational ophthalmology2025
The urinary 6-sulfatoxymelatonin level in patients with central serous chorioretinopathy and its correlation with choroidal vasculature.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeTo investigate the changes in melatonin secretion levels and its association with choroidal vasculature parameters in patients with central serous chorioretinopathy (CSC).
methodsIn this study, 30 male patients were enrolled diagnosed with CSC and 30 healthy male controls. The choroidal vasculature system of all participants were assessed using ultra-widefield swept-source optical coherence tomography angiography (UWF-SS-OCTA). Specifically, we measured choroidal vascular volume (CVV), choroidal vascularity index (CVI), and choroidal thickness (CT). Additionally, the levels of urinary 6-sulfatoxymelatonin(6-SMT) in participants were determined using enzyme-linked immunosorbent assay. Finally, the correlations between normalized 6-SMT and choroidal vascular parameters were evaluated in CSC and controls.
resultsThe levels of urinary normalized 6-SMT in CSC patients (24.8, 20.2 - 28.1) were significantly lower than the control group (36.1, 30.0 - 45.2, P < 0.001). Compared with the control group, CSC patients exhibited significantly larger average CVV, CVI, and CT (CVV: 44.6 ± 8.9 mm
conclusionThis study found that CSC patients had lower levels of urinary 6-SMT. The concentration of 6-SMT was associated with choroidal vasculature parameters. The decrease in melatonin secretion might be a risk factor for CSC.
Indexed as
Identifiers
41231419What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.